| π‘ TO EVALUATEπ‘ TO EVALUATE | 2026-04_ASST_Melegnano | coagulazione POCT | N/A | 97.977 | 27% | medium | In focus (POCT coagulation) but the tender documentation in the dossier is incomplete (only the economic offer): deadline and CIG unknown; verify the availability of the ACT-LR product and the specifications on SINTEL.ACT rental with requirements that are not excluding based on the available data: a potentially contestable opportunity, to be verified against the Firsteck portfolio (ACT-LR system for ECMO). |
| π‘ TO EVALUATEπ‘ TO EVALUATE | 2023-07_TorVergata | coagulation POCT; rapid tests (ACT) | historical / market survey | β | 41% | medium | Fully on-target (ACT POCT) but only a historical market survey; requirements possibly designed around a specific micro-drop technology.Fully on-target (ACT POCT) but only a historical market survey; requirements possibly designed around a specific micro-drop technology. |
| π΄ NO-GOπ‘ TO EVALUATE | 2026-05_AUSL_Romagna | coagulation POCT; molecular biology (respiratory) | expired | 39.352.500 | 89% | high | Doubly in focus and of enormous value, but deadline expired (06/05/2026); moreover the AQURE middleware constraint (Lot 1) and the anti-China IPI measure (β€50% Chinese devices) are potential showstoppers.Enormous prize: Lot 2 (4-target molecular respiratory panel) would have been a great opportunity if Firsteck had the CE-IVDR combo; Lot 1, however, is penalised by the AQURE middleware constraint and the anti-China IPI measure. |
| π΄ NO-GOπ΄ NO-GO | 2023-09_Pavia_14038205 | coagulazione POCT; test rapidi | historical/outcome | 214.920 | 83% | high | Tender already awarded to Instrumentation Laboratory (single-supplier procedure, deadline expired 10/11/2023); POCT requirements with ACT-LR oriented toward a single platform.Single-supplier negotiated procedure awarded to Instrumentation Laboratory (Werfen): not contestable by design. |
| π΄ NO-GOπ΄ NO-GO | 2026-04_Bando_esplorativo | POCT; coagulazione POCT; immunometria/test rapidi | expired | 99.450 | 34% | high | Deadline already expired (notice 16/04/2026, estimated deadline ~26/04/2026) and proprietary consumables tied to installed Abbott analyzers: strong non-substitutability risk, participation possible only with documented equivalent products.NON-SUBSTITUTABILITY verification on proprietary Abbott consumables (i-STAT/Stat Alinity): contestable only by demonstrating equivalence with compatible products, very difficult. |
| π΄ NO-GOπ΄ NO-GO | 2021-12_ASST_Garda | coagulazione POCT (ACT) | historical/outcome | 91.152 | 50% | high | Already awarded 2022-2028 to Instrumentation Laboratory/Werfen. Price benchmark only, not an open opportunity.Market controlled by Werfen (Instrumentation Laboratory, Hemochron in-service system): hard to attack even in an open tender without an equivalent, compatible ACT system. |
| π΄ NO-GOπ΄ NO-GO | 2024-06_VR | coagulazione POCT; POCT | expired | 85.000 | 55% | high | Offer deadline expired on 28/08/2024 (historical tender) and the Celite method + TD-Synergy interface requirement is oriented towards a specific supplier (Hemochron/Werfen).The 'Celite method' requirement is typical of Hemochron systems (Werfen/Accriva): effectively oriented towards the incumbent, low contestability regardless of timing. |
| π΄ NO-GOπ’ GO | 2023-04_Biella | coagulazione POCT; test rapidi; POCT | expired | 69.600 | 41% | low | Expression of interest expired since 06/04/2023 (over 3 years ago) and award most likely already concluded: out of time despite the product being fully within focus and the requirements not being exclusionary.REAL opportunity: GENERIC cartridge-based POCT requirements, no brand or middleware constraint. Contestable by Firsteck if a suitable ACT system is in the catalog. The 'real' NO-GO depends ONLY on the past deadline. |
| π΄ NO-GOπ΄ NO-GO | 2021-12_ASST_Mantova | coagulazione POCT | historical/outcome | 58.340 | 39% | high | Contract already awarded to Instrumentation Laboratory in 2021 with a contract expired in 2023; no open tender and strong lock-in on the outgoing supplier.Service supply historically held by Instrumentation Laboratory (Werfen) and low volumes: a barely contestable opportunity even disregarding the expiry. |
| π΄ NO-GOπ΄ NO-GO | 2022-09_Cagliari | coagulazione POCT | expired | 49.000 | 31% | high | 2022 market survey long expired and captive consumables tied to the ACT coagulometers (Hemochron codes) owned by the organisation: Firsteck cannot offer a compatible product.'Captive' consumables tied to the Hemochron coagulometers ALREADY owned by the organisation: not contestable without that analyser, regardless of timing. |
| π΄ NO-GOπ΄ NO-GO | 2023-02_Perugia | coagulazione POCT; test rapidi | expired | 36.000 | 45% | high | Preliminary market consultation expired since 06/02/2023 with a declared single operator and unique technical requirements: out of time and at high exclusivity risk.Consultation with a declared single operator/unique requirements: opportunity effectively closed in substance, not only due to timing. |
| π΄ NO-GOπ‘ TO EVALUATE | 2023-02_SantAndrea | coagulazione POCT; test rapidi | historical/outcome | 22.000 | 34% | medium | Market survey expired on 20/02/2023 (over 3 years ago): out of deadline, not participable; in focus but historical.Annual direct award: microdrop requirements may steer but do not entirely exclude. Opportunity conditional on the availability of a suitable ACT system. |
| π΄ NO-GOπ‘ TO EVALUATE | 2023-09_Pavia_13993558 | coagulazione POCT | historical/outcome | β | 45% | low | Non-binding expression of interest with a 15/09/2023 deadline largely expired; although fully in focus (POCT coagulation) it is no longer submittable.POCT coagulation expression of interest (PT/APTT/ACT) with generic requirements: in principle contestable, depended on the catalogued system. |